Stockreport

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or via [Read more]